Erythropoietin (EPO) is a candidate compound for neuroprotection in human brain disease capable of combating a spectrum of pathophysiological processes operational during the progression of schizophrenic psychosis. The purpose of the present study was to prepare the ground for its application in a first neuroprotective add-on strategy in schizophrenia, aiming at improvement of cognitive brain function as well as prevention/slowing of degenerative processes. Using rodent studies, primary hippocampal neurons in culture, immunohistochemical analysis of human post-mortem brain tissue and nuclear imaging technology in man, we demonstrate that: (1) peripherally applied recombinant human (rh) EPO penetrates into the brain efficiently both in rat and humans, (2) rhEPO is enriched intracranially in healthy men and more distinctly in schizophrenic patients, (3) EPO receptors are densely expressed in hippocampus and cortex of schizophrenic subjects but distinctly less in controls, (4) rhEPO attenuates the haloperidol-induced neuronal death in vitro, and (4) peripherally administered rhEPO enhances cognitive functioning in mice in the context of an aversion task involving cortical and subcortical pathways presumably affected in schizophrenia. These observations, together with the known safety of rhEPO, render it an interesting compound for neuroprotective add-on strategies in schizophrenia and other human diseases characterized by a progressive decline in cognitive performance.
Introduction
The discovery of dopamine antagonists in the middle of the last century represents a major achievement for psychiatry, in general, and for the treatment of schizophrenic psychosis, in particular.
1 Dopamine antagonists delivered a new class of drugs, neuroleptics, which are capable of reducing or eliminating psychotic symptoms. Patients tend to return 'to normal' with respect to their most obvious behavior and their compliance towards treatment. Underneath this 'normalization', however, there is a silently, slowly and nondramatically progressing deterioration of cognitive functioning. [2] [3] [4] [5] This deterioration shows gradual differences among patients with the most severely affected individuals representing Kraepelin's 'dementia praecox'. 6 Brain atrophy and ventricular enlargement as morphological substrates of this continuous cognitive decline have been suspected for decades using autopsy material and imaging studies. 5, 7, 8 A pivotal long-term follow-up study of brain morphology in first episode schizophrenia has revealed progressive ventricular enlargement, consistent with a neurodegenerative process. 9 Another recent study, also based on high-resolution magnetic resonance imaging, found dynamic patterns of accelerated gray matter loss in the brains of childhoodonset schizophrenia with earliest defects in the parietal association cortex. 10 Gray matter loss in parietal cortex is known to be strongly associated with environmental factors. 11, 12 The deficits described in the study intensified and spread over 5 years of disease progression frontally to the prefrontal cortex and to temporal brain regions, indicative of ongoing degenerative processes. 10 At the cellular level, these processes may involve an increased postnatal rate of neuronal apoptosis/pruning, metabolic alterations of neurons, loss of axons, and reduced synaptic sprouting/altered neuroplasticity. 5, 13, 14 With respect to molecular mechanisms, atypical gene expression, for example, of Oct-6 15 or of apolipoprotein L, 16 has been identified in the brains of schizophrenic patients. The accelerating impact of neurotrauma on the development of schizophrenia has already been described by Kraepelin 6 and confirmed later in epidemiological studies. [17] [18] [19] Taken together, these findings point to an important role of neurodegenerative components in the pathophysiology of schizophrenia next to the more readily accepted neurodevelopmental aspects of the disease. 5, 13, [20] [21] [22] In fact, it becomes increasingly difficult, and perhaps also unreasonable, to draw a line between neurodevelopmental and neurodegenerative processes in schizophrenia.
Recognition of neurodegenerative components in turn urges for an early application of neuroprotective strategies as 'add-on therapy' to the predominantly symptomatic antipsychotic treatment of schizophrenic psychosis. Unfortunately, there is no satisfying animal model for schizophrenia that would allow sufficient prediction of the efficacy of neuroprotective treatment in man. Existing models at best represent certain aspects of this complex human disease. 23 Some behavioral phenomena resulting from information processing disturbances in schizophrenic patients can also be observed in animals, for example, poor associative learning or disruption of latent inhibition, as measured for instance with the conditioned taste aversion (CTA) paradigm. Latent inhibition is the retardation of associative conditioning resulting from pre-exposure to the conditioned stimulus alone prior to conditioning. [24] [25] [26] CTA tests an animal's ability for learning to associate illness with a novel taste stimulus, such that the animals avoid the novel taste upon subsequent re-exposure to the novel stimulus. CTA involves the brain at a variety of cortical and subcortical levels. The association that links ascending and descending information together producing aversive behavior can be either attenuated or strengthened by changes affecting the medial septum 26 or any other of the interconnecting units. For example, the nucleus accumbens is involved in aversive conditioning and this area may be key to psychotic symptoms. 27, 28 Agents enhancing CTArelated cognitive functions may have some potential to influence certain aspects of cognitive deterioration positively in schizophrenia and should, therefore, be considered as candidate compounds for neuroprotection in this disease.
Neuroprotection may be defined as the attempt to maintain the highest possible integrity of cellular interactions in the brain, id est protection of neural function. 29 A candidate compound, addressing the pathophysiological mechanisms involved in the progression of schizophrenic psychosis, is erythropoietin (EPO). EPO exerts antioxidant, antiapoptotic, antiinflammatory, neurotrophic, angiogenic and synaptogenic activity. [30] [31] [32] Encouraging results on its neuroprotective power in man have been obtained from our recent treatment trial in stroke patients. 33 Thus, neuroprotection in principle can work in man. Although ischemia as an acute and schizophrenia as a chronic condition do not compare with respect to etiology and pathogenesis, there are final common pathways, for example, metabolic distress and/or lack of trophic intercellular support that can be expected to respond to a neuroprotective treatment. EPO has been in clinical use for over a decade and has been found to be well tolerated. Its chronic administration over the years has saved lives of thousands of patients suffering from chronic renal failure. 34 Thus, one prerequisite for a candidate compound for neuroprotection in schizophrenia would be fulfilled: safety. In addition, such a compound has to (1) be presumably effective in improving cognition and/or slowing the degenerative process, (2) be capable of crossing the blood-brain barrier, and (3) have receptive structures in the brains of schizophrenic patients. The aim of the present study was to address these prerequisites for EPO-treatment of schizophrenia and thereby to create the basis for a first neuroprotective add-on strategy in this disease.
Materials and methods

Rodent studies
All experiments had received approval by the local Animal Care and Use Committee.
Measurement of EPO immunoreactivity in rat CSF after intraperitoneal
administration In order to demonstrate directly that EPO can, in fact, transfer from the systemic circulation into the brain, recombinant human (rh)EPO was injected intraperitoneally (i.p.) into normal rats (5000 U/kg) and serial samples of CSF were obtained from the cisterna magna for EPO determination. 35 The CSF concentrations of EPO were measured by an ELISA (R&D Systems, Minneapolis, MN, USA) using the manufacturer's protocol. The sensitivity of the assay is approximately 2 mU/ml.
CTA Female Balb/c mice were trained to limit their total daily water intake to a single 5 min drinking period per day, and learned to drink enough water during this period to remain at equilibrium. Animals were divided into groups and administered either saline or rhEPO (5000 U/kg), injected i.p. 4 h before presentation of a novel saccharin-vanilla liquid. Immediately after finishing drinking the sweet liquid, animals received either saline or an illnessproducing dose of lithium (20 mg/kg of a 0.15 M LiCl, delivered i.p.). Thereafter, three groups of animals were followed for 21 days. The first group (sham) did not receive lithium after drinking. The second group (rhEPO) received both rhEPO and lithium. The third group (control) received saline (without rhEPO) and lithium.
In vitro experiments
Culture of hippocampal neurons Hippocampal neurons were prepared and cultured according to Brewer 36 with slight modifications. Briefly, hippocampi were removed from a newborn WistarImamichi rat into a dish containing Hank's balanced salt solution (HBSS) supplemented with 0.1% glucose, 1 mM NaHCO 3 , 1 mM pyruvate, 10 mM HEPES and B27 (Invitrogen, Karlsruhe, Germany). Hippocampi were incubated for 30 min with papain (2 mg/ml, Sigma, Taufkirchen, Germany) on a rotating plattform, followed by trituration. Cell suspension was underlayered with a density gradient prepared in four 1-ml steps of 35, 25, 20 and 15% of Optiprep (Nycomed, Oslo, Norway) in HBSS/B27 (v/v). The cell suspension was centrifuged for 15 min at room temperature, 800 g (1900 r.p.m.). Neuron-enriched fractions were collected, washed with 5 ml of HBSS/ B27, and centrifuged (200 g, room temperature, 1 min). The pellet was resuspended in serum-free growth medium (NeurobasalA/B27 (Invitrogen) with 5 ng/ml of basic fibroblast growth factor (bFGF, Invitrogen), 0.5 mM L-glutamine (Sigma), 50 U/ml of penicillin and 50 mg/ml of streptomycin (Boehringer Mannheim, Germany)). Neurons were plated on poly-D-lysine (Sigma) coated 12 mm coverslips in fourwell-plates (Nunc, Wiesbaden, Germany), at a density of 50 cells/mm 2 . Cultures were grown in a humidified incubator at 371C, 5% CO 2 . For testing the biological (ie protective) effect of labeled rhEPO (see below), DTPA-rhEPO or In-DTPA-rhEPO (10 À10 M) were added to the cultures on day 5 together with fresh medium (first medium exchange). The 15-h hypoxia condition was started immediately thereafter as described previously. PCR reactions were carried out in a final volume of 20 ml in glass capillaries on a LightCycler real-time PCR machine (Roche Biochemica, Mannheim, Germany). The reaction mixture consisted of 1 ml cDNA solution, 1 U Taq DNA polymerase (PANScript DNA Polymerase, PAN Biotech, Aidenbach, Germany), 2 ml 10 Â PCR buffer (Invitrogen, Karlsruhe, Germany), 0.2 mM each dATP, dCTP, dGTP and dTTP (Roche Biochemica), 3 mM MgCl 2 , 500 mg/l bovine serum albumin (New England BioLabs, Frankfurt, Germany), 50 ml/l dimethylsulfoxide (Sigma, Munich, Germany) and SYBR Green I (Molecular Probes, Eugene, OR, USA) at a final concentration of 1 : 10 000. Amplification primers were used at 1 mM concentration. PCR grade water was added to 20 ml. Due to the low EPOR expression in neurons under normoxic conditions, this PCR was optimized by the addition of dsDNA fragments to resemble hotstart conditions and improve the detection sensitivity. 38 Fragments 5 0 AGC GGA TAA CAA TAT CA and 5 0 TGA TAT TGT TAT CCG CT (3 mM) were annealed and incubated for 15 min in the PCR mixture excluding amplification primers to inhibit the polymerase. PCR primers were then added and PCR cycling commenced. The cycling program consisted of 30 s of initial denaturation at 951C and 45 cycles of 951C, 0 s; 551C, 5 s and 721C, 5 s, with maximum ramp rate. The acquisition temperature was chosen above that of primer dimers to avoid interference with the detection of the specific PCR product. Acquisition temperature for the EPOR PCR was 87 and 841C for the EF-2 PCR.
Labeling of rhEPO
All chemicals were purchased from Sigma-Aldrich (Dreieich, Germany) if not otherwise indicated. 111 InCl 3 was obtained from Mallinckrodt (Hennef, Germany). Recombinant human (rh) EPO was kindly provided by Janssen Research Foundation (Titusville, NJ, USA).
DTPA derivatization and labeling of rhEPO A measure of 1.7 mg rhEPO was rebuffered with 5 Â 5 ml 0.1 M NaHCO 3 on a 10 kDa size exclusion filter unit (Millipore Corporation, Bedford, MA, USA) to a final volume of 500 ml. Thereafter, 10 mg of diethylene-triamine-penta-acetic acid anhydride (cDTPA) in 20 ml DMSO were added and incubated for 1 h at room temperature. This step was repeated once. Afterwards, the reaction mixture was rebuffered with 5 Â 5 ml 0.5 M sodium acetate, pH 5.4, on the size exclusion filter to a final volume of 200 ml. The Erythropoietin for schizophrenia H Ehrenreich et al content of DTPA-rhEPO was evaluated by UV-VIS spectrometry at 275 nm to be 8.2 mg/ml.
Cold In-labeling procedure A volume of 500 ml of 10 À3 M InCl 3 in 0.1 M HCl was added to DTPA-rhEPO solution (1 mg/500 ml 0.5 M sodium acetate buffer, pH 5.4) and incubated at 371C. Quality control was performed over a PD-10 size exclusion column with 0.5 M sodium acetate buffer, pH 5.4, with a fraction size of 500 ml. The In-DTPA-rhEPO was purified and rebuffered with PBS via a 10 kDa filter. The exact amount of rhEPO content was evaluated with UV/VIS spectroscopy.
Hot In-labeling procedure A volume of 500 ml of 2 Â 10 À6 M InCl 3 in 0.1 M HCl with 10 mCi 111 InCl 3 (1.5 Â 10 À10 mol) was added to 0.41 mg DTPA-rhEPO solution in 500 ml 0.5 M sodium acetate buffer, pH 5.4, and incubated at 371C. Quality control was performed over a PD-10 size exclusion column with 0.5 M sodium acetate buffer, pH 5.4, with a fraction size of 500 ml. Purification for patient studies was performed in the same way with PBS.
Analysis of In-111 in human cerebrospinal fluid (CSF) and serum samples A volume of 2 ml of CSF or serum was added on a Sephadex G-50 column (1 Â 10 cm) and eluted with PBS at a fraction size of 500 ml. Samples were counted in a gamma counter. For comparison, a standard mixture of In-111-rhEPO and In-111 was measured.
Patients and controls
The present study has been approved by the Ethical Committee of the Medical Faculty of the GeorgAugust-University, Goettingen, as well as by the German Nuclear Regulatory Agency. Five patients and five healthy controls, all male, participated after informed written consent. Patients were 20-35 years old (mean7SD¼25.075.9 years). Consensus diagnosis of schizophrenia, either primarily paranoid or hebephrenic (according to DSM IV criteria), had been made 3.673.2 (1-9) years ago and has now, for study participation, been confirmed and completed by structured interview and chart reviews. Upon entering the study, the present episode had lasted for 1-3 weeks. The five controls were 23-32 years old (mean7SD¼27.673.6 years; P¼0.43 as compared to patients). Patients and controls did not differ with respect to routine laboratory parameters including white and red blood cell count, hematocrit, hemoglobin and thrombocytes. All patients were on antipsychotic medication at the time of testing (risperidone, olanzapine, flupenthixol or perazine).
In-111-rhEPO-scintigraphy
The In-111-rhEPO scans were performed in the five patients and five controls at 4 time points, i.e. 0.5-1, 4-4.5, 18-24, and 42-45 h postinjection (i.v.) of 40 000 U rhEPO containing 120-185 MBq In-111-rhE-PO (ie r5% of total rhEPO injected). Whole-body imaging was performed with a pre-selected time of 30 min using a dual headed gamma camera (Prism 2000, Marconi Medical Systems (formerly PICKER), Cleveland, OH, USA), fitted with a medium-energy collimator. A 128 Â 128 computer matrix and the 171 and 245 keV photopeaks were used. For single photon emission computed tomography (SPECT) of the skull, the same camera and medium-energy collimator were employed, a 3601 circular orbit, 60 stops with 30 s acquisition time each and a 128 Â 128 matrix. Reconstruction was performed by an iterative algorithm (ISA). 39 Following orbitomeatal reorientation, the skull was divided from the base to the vault into 24-32 transversal sections. From these sections, the mid-section was chosen for each subject. A region of interest (ROI) technique was used to generate a quotient between the mean counts per pixel of the intracerebral activity and the mean counts per pixel of the skull (bone marrow) activity in this slice (Q IC/ BM) at 4-4.5, 18-24, and 42-45 h postinjection, respectively ( Figure 3b ).
The biodistribution of the tracer was calculated using the geometric mean method by generating ROIs in anterior and posterior projections over the whole body, liver, spleen, bone marrow and kidneys. The activity of each organ was expressed as percentage of the whole-body activity at the respective time points. Since it is virtually impossible to generate a wholebody bone marrow-ROI, the ROI was determined from the second to fourth lumbar vertebrae and the result was multiplied with 11.23 to correct for the wholebody bone marrow activity. In fact, the hematopoietic bone marrow of the second to fourth lumbar vertebrae in young adults amounts to 8.9% of the whole-body hematopoietic bone marrow. 40 
Immunohistochemical protocol
We had the chance to investigate five autopsy brains of schizophrenic patients (diagnosis based on DSM IV criteria) with a documented duration of disease of 410 years and to compare them to seven control cases who had died from conditions other than neurological/psychiatric disease. All brains, schizophrenic and control, were normal on routine neuropathological examination (for further case details, see Table 1 ). Brains were fixed with 4% paraformaldehyde and then processed for paraffin embedding. The sections were deparaffinized in Hemo-De (Fisher Scientific, Schwerte, Germany), three changes (5 min), rehydrated through graded ethanols, washed with distilled water, boiled in citrate buffer, washed in Tris-buffered saline (TBS), incubated in 10% blocking serum in 0.05% Tween-20/TBS at room temperature and exposed to polyclonal rabbit antihuman EPOR antibodies (1 : 200, C-20, Santa Cruz Biotechnology, Heidelberg, Germany) in 2% goat sera/ PBS at 41C overnight. After washes in 0.05% Tween-20/TBS, the sections were covered with biotinylated goat-anti-rabbit antibodies (1 : 100, Vector Laboratories Inc., Burlingame, CA, USA) for 60 min. After TBS washes (3 Â 10 min), amplification of the signal was carried out by the avidin-biotin (ABC) method with the appropriate peroxidase kit (Vectastain Elite, Vector) and the signal visualized by incubation in 0.06% diaminobenzidine (DAB; Sigma Chemical Co., Deisenhofen, Germany) and 0.006% H 2 O 2 in 0.1 M Tris-HCl (pH 7.6). The slides were dehydrated, cleared, mounted with Eukitt 
Statistical analysis
For statistical analysis of the data, analysis of variance was used. Comparison of individual means was performed using the Mann-Whittney U-test or the Student's t-test, with Pr0.05 considered to be statistically significant.
Results
Rodent studies
Recovery of immunoreactive EPO in rat CSF Prerequisite for application of rhEPO in brain disease without regularly disturbed blood-brainbarrier function is its transfer over this barrier. As shown in Figure 1a , intraperitoneal injection of rhEPO (5000 U/kg body weight) in healthy rats led to an increase in CSF EPO immunoreactivity, peaking at 3.5 h.
Cognitive performance in mice upon intraperitoneal treatment with rhEPO This set of mouse studies was performed in order to explore the potential of rhEPO to influence cognitive tasks representing some aspects of cognition compromised in schizophrenia. CTA was measured by determining the reduction in drinking upon subsequent exposure to an illness-producing solution, novel saccharin-vanilla liquid, in three groups of mice treated with (1) rhEPO and lithium (rhEPO), (2) saline and lithium (control), (3) saline Figure 1b . Day 3 represents the baseline consumption of water after habituation to the test cage. On Day 4, animals received an injection of either saline or rhEPO (5000 U/kg i.p.) 4 h before presentation of the novel saccharin-vanilla fluid, followed by treatment with lithium or saline. This treatment resulted in a small decrease in fluid consumption in all groups on Day 4, a previously documented adverse effect of the injection and novelty of the fluid. After recovery for 5 days, the first test for the establishment of a CTA showed no decrease in consumption for controls. However, animals having received lithium demonstrated a virtually complete aversion to the fluid, in spite of being water deprived (Day 9). Continued deprivation of water eventually produced an extinction of the CTA, but was characterized by a markedly delayed recovery by the animals that had received rhEPO, as shown by the filled circles in Figure 1b . The robustness of the CTA established herein is better appreciated by considering the degree of water deficit in lithium treated mice followed on each test day, as the rhEPO-treated animals tolerated a water deficit approximately twice that of control (saline injected) mice (Figure 1c ).
Cell culture experiments
Effect of rhEPO on haloperidol-induced neuronal death These experiments have been performed to collect first in vitro evidence for a potential interaction of the prototype classical neuroleptic haloperidol and rhEPO on neuronal survival in culture. In agreement with previous reports, haloperidol led to an increased death rate of cultured hippocampal neurons at a concentration of 10 À6 M. 41 This increased cell death could be significantly reduced by the addition of rhEPO (Figure 2a) . Quantitative real-time RT-PCR was then performed to determine whether the protective effect of rhEPO on haloperidol-induced cell death might be explained by an upregulation of EPOR under these circumstances. Quantification of EPOR mRNA copies, however, did not reveal differences between neurons Purification and biological activity of In-DTPA rhEPO The labeling yield of In-DTPA rhEPO was about 69% and the radiochemical purity after purification was over 95% (Figure 3a) . In order to determine whether primary hippocampal neurons in culture would be protected against hypoxia-induced cell death by In-DTPA-labeled rhEPO in a fashion comparable to native rhEPO, we applied highly purified In-DTPA rhEPO as well as DTPA-rhEPO to cultures exposed to hypoxia for 15 h. 31, 37 Figure 2b shows that the protective effect of rhEPO is not altered by labeling with DTPA or In-DTPA.
Human studies
No side effects and no complaints of the participating patients and controls were identified throughout the study. Two schizophrenic patients missed one SPECT session each and one of them missed one session of whole-body imaging due to a scheduling conflict. All other parts of the study could be completed by all participants.
Determination of ROIs for estimating the relative amount of radioactivity in the brain In order to estimate the relative amount of In-111 rhEPO in the brain, ROIs were determined as shown in Figure 3b . These ROIs allowed the calculation of the ratio between the mean counts per pixel of the intracerebral activity and the mean counts per pixel of the skull (bone marrow). In Figure 4 , representative and comparable sections, one per subject, are presented that are taken from the 24-h time point. The line-graphs next to the sections show the ratio, determined as described above, of radioactivity at the 4-4.5-, 18-24-and 42-45-h time points. From the screening of the sections and even more so from the calculation of these ratios, it became evident that the relative activity in the brains of schizophrenic Profile of In-111 labeled rhEPO and its metabolites in CSF and plasma Figure 5b displays the chromatogram of the CSF from a patient who could be lumbar punctured 36 h after injection of In-111 rhEPO. There is a considerable amount of radioactivity co-eluting with the In-111 rhEPO standard peak. A smaller part of the radioactivity co-elutes with the free In-111 position of the standard (low molecular weight In-111 fractions). Interestingly, there is another peak between these two standard positions that may represent an unknown major metabolite of In-111 rhEPO in the CSF. The serum activity (Figure 5a ) is nearly 100 times higher and consists predominantly of the In-111-rhEPO peak. This dominating peak may hide the presence of relatively minor amounts of metabolites.
Distribution of In-111-rhEPO in whole body of healthy and schizophrenic young men Table 2 shows the relative distribution pattern of radioactivity in healthy subjects and schizophrenic patients at 0.5-1-, 4-4.5-, 18-24-and 42-48-h time points after the injection of In-111-DTPA rhEPO. At all time points, there is also a distinct radioactivity found in the bone marrow of the vertebrae. Interestingly, the relative radioactivity in the bone marrow of schizophrenic patients is higher at all time points (significant at 18-24 and 42-48 h) than in controls, whereas the percentage of radioactivity in the other organs is comparable in both groups. Hematocrit, hemoglobin and red blood cell count were normal in all subjects and did not differ among groups (data not shown).
Immunohistochemical staining for EPOR in the brains of schizophrenic patients vs controls To see whether the central nervous system of schizophrenic subjects contains receptors for EPO, brains from schizophrenic patients who died under 'non-brain-related' circumstances, were examined ( Table 1) . As shown in representative slides in Figure 6a , there is a distinct staining of neurons in the hippocampus of schizophrenic patients. Double immunofluorescence using the neuronal marker NeuN reveals that EPOR immunoreactivity is localized to neurons (Figure 6b) . Moreover, GFAP-positive astrocytes (Figure 6f intensity, these differences reached statistical significance (Figures 6g and h ). The specificity of these findings was underlined by determination of the staining intensity and distribution of an unrelated antigen, the cannabinoid type 1 (CB1) receptor, in neighboring sections of the same brains. Employing CB1 antibody resulted in an equally strong neuronal staining in hippocampal and cortical sections from both control and schizophrenic patients.
Discussion
Collectively, these data demonstrate that (1) peripherally applied rhEPO is able to penetrate efficiently into the brain even across an intact blood-brain barrier both in rat and in humans, (2) it is enriched intracranially in healthy men and even more distinctly in schizophrenics, where a remarkable EPOR expression in hippocampus and cortex is found, (3) rhEPO counteracts haloperidol-induced neuronal death in vitro, and (4) peripherally administered rhEPO enhances cognitive functioning in mice in the context of an aversion task involving cortical and subcortical pathways presumably affected in schizophrenia.
The present work has addressed the question whether rhEPO might be suitable as a neuroprotective treatment (prophylactic as well as therapeutic) of schizophrenia. For this severely disabling disease, predominantly affecting young people, no satisfying animal model is available. 23 This justifies the use of well-tolerated candidate compounds in humans. Based on positive results of well-designed proof-ofprinciple trials in schizophrenia, it may be worthwhile and even necessary to go back to animal studies employing available animal models 23, 42, 43 to explore mechanisms of action of the neuroprotectant in a particular setting that reflects defined aspects of this devastating human disease. The animal model applied here addresses such a defined aspect. CTA, an associative learning task known for its robustness, reveals that intraperitoneally applied rhEPO enhances the ability of mice to remember, and learn to avoid, despite excessive water deficit/thirst, an unpleasant taste sensation. As a form of classical conditioning, the strength of CTA is determined by a large number of variables including novelty of the oral stimulus (non-novel stimuli cannot be aversively conditioned), degree of 'illness' produced (toxicity), number of repetitions (training), countering drives (such as thirst) to name a few. Although a wide variety of chemical and physical agents can produce CTA in a dose-dependent manner, lithium chloride reliably produces malaise and anorexia. Like a naturally Table 2 Relative distribution of In-111-rhEPO in whole body and peripheral organs of healthy and schizophrenic young men
occurring illness, lithium produces a CTA by stimulating cortical and subcortical pathways, including cytokine release. 24, 26 The positive results obtained with rhEPO in this context encourage pilot trials of rhEPO in schizophrenia since comparable properties are thought to be affected in this disease. 25, 27 A chronic disease like schizophrenia most likely requires chronic application of a neuroprotectant. In this regard, the positive experience with long-term application of rhEPO in patients suffering from renal anemia 34, 44 alleviates the concern that the use of rhEPO in schizophrenia might cause major side effects. An increase in hematocrit, the main hematopoietic effect of EPO, can be corrected by bloodletting. Potentially relevant side effects to be considered based on long-term observations in renal failure and cancer patients would include hypertension 45 and, as extensively investigated more recently, formation of neutralizing anti-EPO antibodies harboring the risk of developing erythroblastopenia. This latter phenomenon has been reported in a total of about 170 cases, all suffering from renal anemia, all on long-term treatment, all having had subcutaneous applications of EPO 46 (and information from the manufacturer).
Interestingly, cognitive improvement in renal failure patients upon rhEPO treatment had been observed long before the EPO system has been detected in the brain. This cognitive amelioration was attributed to increases in hematocrit. 34, 44 Controlled studies addressing this topic are lacking. The fact, however, that rhEPO induces cognitive improvement before an increase in hematocrit is noted, makes it very likely that ameliorated cognition reflects a direct effect of rhEPO on the central nervous system. 47 A molecular separation of these two properties of EPO could be demonstrated by recent findings of potent neuroprotective effects of desialylated EPO (asialoEPO), which is devoid of any hematopoietic activity. 48 Hereby, the antioxidant properties of EPO, rapidly improving the metabolic/trophic situation in the brain may play an essential role. 49, 50 Additional long-term beneficial effects of an increased hematocrit, however, cannot be excluded.
In-111-DTPA rhEPO was developed and employed for the first time to investigate the distribution of intravenously applied rhEPO in brain and whole body of healthy vs schizophrenic patients. This method should assist in estimating the degree of penetration of rhEPO into the brain via an intact blood-brain barrier. Using this approach, an unexpectedly high amount of radioactivity was detected in the brains of both, healthy and schizophrenic patients. This high amount became evident already at the 4-h time point and persisted for at least 2 days. The nature of radioactivity could be attributed by chromatographic examination of CSF to approximately 50% intact EPO. Although there was, expectedly, a much higher concentration detectable in serum, the distribution of rhEPO into the brain, comparable to that seen in stroke patients, 33 may be sufficient for exerting its neuroprotective activity also in chronic conditions. Considering the high molecular weight of rhEPO (434 000 Da), its rapid penetration across an intact blood-brain barrier could be explained by a transport mechanism. In fact, it has previously been demonstrated that few hours after intraperitoneal application, biotinylated rhEPO densely surrounds cerebral microvessels of mice, supportive of an active translocation process. 32, 51 The relative amount of radioactivity in the bone marrow of schizophrenic patients was found to be higher as compared to controls despite comparable hematological parameters and comparable distribution in liver, spleen and kidney. At present, the reason for this discrepancy is a matter of speculation. One possibility may be that chronic treatment with dopamine antagonists increases the density of EPOR in bone marrow and brain. All patients, those who participated in the SPECT study and those from whom post-mortem brain samples were analyzed for EPOR immunoreactivity, have been on neuroleptic medication; the former on atypical, the latter on classical antipsychotics. Thus, it cannot be excluded that dopamine antagonists enhance the transfer of rhEPO across the blood-brain barrier and/or increase rhEPO binding to brain cells. In accordance with the finding of a higher accumulation of radioactivity in the brains of schizophrenic patients, a higher density of immunoreactive EPOR in schizophrenic brains was demonstrated by immunohistochemistry. Chronic therapeutic dopamine antagonism as potential explanation of augmented rhEPO binding in schizophrenic patients is currently under investigation in our laboratory. If there is a causal connection responsible for the observed phenomenon, it certainly is a complex one. The preliminary data presented here using quantitative real-time RT-PCR to measure EPOR mRNA expression of neurons in vitro upon exposure to haloperidol did not uncover any change at the message level. Such change, however, can be observed upon another cell death-promoting stimulus, hypoxia. 37 In any case, the protective effect of rhEPO on haloperidol-induced neuronal death in vitro may further support the use of rhEPO as neuroprotective add-on therapy in schizophrenia.
In addition to a potential role of chronic dopamine antagonism, the coincidence of a higher accumulation of radioactivity both in brain and bone marrow of schizophrenic men as compared to controls would at least allow one alternative explanation: Persistent metabolic distress in schizophrenia may induce a chronic stimulation of stem cells that could explain a higher density of EPOR in stem cell providing tissues. Such constant stem cell activation would be consistent with the neurodevelopmental hypothesis of schizophrenia. 5, 13, [20] [21] [22] Interestingly, the EPO-system appears to play a major role during embryonic brain development. 52, 53 A recent paper shows that EPO regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. 53 Considering that pathophysiological processes in schizophrenia appear to be composed of neurodevelopmental as well as of neurodegenerative aspects, 5, 22 it may be speculated that also metabolic disturbances due to neurodegenerative processes stimulate the endogenous EPO system 30 leading to a higher density of EPOR expression not only in neurons but also in glial cells. Various metabolic disturbances in schizophrenia have been shown by several groups. 54, 55 Interestingly, glial cells appear to be more and more recognized as important players in schizophrenia pathophysiology. 56, 57 Although the situation in ischemic stroke is not directly comparable to the situation of neurodegeneration in schizophrenia, it is interesting to note that blocking of the endogenous EPO system by using soluble EPOR leads to a dramatic increase in lesion size in an experimental stroke model. 32 Should theperhaps relatively deficient-endogenous EPO system in schizophrenics profit from exogenous substitution? It is encouraging that the Goettingen EPO-Stroke Trial has demonstrated for the first time the efficiency of a neuroprotective strategy in humans using EPO. 33 In animal models, EPO has been able to improve the outcome in both acute and chronic disorders. 32, 51, 58 The conditions tested range from various animal models of cerebral ischemia/hypoxia 32, 51 and neurotrauma 51 to epilepsy 51 , Parkinson syndrome 58 or experimental autoimmune encephalitis. 51 These observations together with the results of the present study render EPO an interesting compound for neuroprotective add-on strategies in schizophrenia and other human diseases characterized by a decline in cognitive performance. A multicenter proof-of-concept trial in schizophrenia has started in Germany in April 2003.
